Tykerb — CareFirst (Caremark)
Recurrent EGFR-positive chordoma
Initial criteria
- Treatment of EGFR-positive recurrent chordoma as a single agent
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months